MPS III Sanfilippo Syndrome Plasma

About MPS III Sanfilippo Syndrome Plasma

MPS III Sanfilippo Syndrome Plasma for Lysosomal Storage Disease Research

MPS III Sanfilippo Syndrome Plasma is collected from IRB-consented donors with a clinically confirmed diagnosis of mucopolysaccharidosis type III and processed under rigorous, standardised SOPs with donor screening and sample quality checks. Plasma is acellular, so this product is supplied for soluble-analyte work — glycosaminoglycan quantification, immunoassay, proteomics and metabolomics — in standard or custom volumes with de-identified clinical annotation.

Why MPS III Plasma for Genetic Disease Research

Sanfilippo syndrome is a monogenic autosomal recessive lysosomal storage disease. A deficiency in one of four enzymes required for the stepwise degradation of heparan sulfate blocks the catabolic pathway, so partially degraded heparan sulfate accumulates in lysosomes throughout the body and particularly in the central nervous system. The consequence is progressive neurodegeneration with developmental regression, behavioural disturbance and loss of acquired skills. This is a defined genetic and biochemical defect, not an autoimmune process.

• Heparan sulfate accumulation — the primary storage material is measurable in the circulation, making plasma glycosaminoglycan quantification the most direct biochemical readout of the underlying defect.
• Four enzyme subtypes, one pathway — MPS IIIA (SGSH, heparan-N-sulfatase), IIIB (NAGLU, alpha-N-acetylglucosaminidase), IIIC (HGSNAT, acetyl-CoA:alpha-glucosaminide N-acetyltransferase) and IIID (GNS, N-acetylglucosamine-6-sulfatase) each block a different step in heparan sulfate degradation.
• Non-reducing-end structural signatures — the specific enzyme deficiency determines the terminal structure of the accumulated heparan sulfate fragments, which is central to subtype-discriminating biomarker methods.
• Secondary consequences of storage — lysosomal dysfunction, disrupted autophagy and secondary accumulation of other substrates generate downstream analytes detectable in the acellular compartment.
• Neurodegeneration markers — circulating markers of neuroaxonal injury and neuroinflammation are of active interest as peripherally accessible surrogates for a primarily central disease.
• Therapeutic development context — enzyme replacement, gene therapy and substrate reduction programmes all need plasma heparan sulfate and related analytes as pharmacodynamic endpoints, since a plasma sample can be collected repeatedly where CSF cannot.

Donor Stratification Available

• Enzymatic and genetic subtype — MPS IIIA (SGSH), IIIB (NAGLU), IIIC (HGSNAT) and IIID (GNS), subject to documentation and availability
• Genotype and variant detail — specific pathogenic variants where genetic confirmation is available
• Disease stage — early or pre-regression, active neurological regression, and advanced disease
• Age at collection — paediatric donors through to attenuated-phenotype adolescent and adult donors where available
• Treatment and trial status — treatment-naive donors and donors enrolled in or previously exposed to investigational therapy, subject to documentation; obligate carriers available on request
• Matched healthy controls available, age- and sex-matched and collected on the same protocol

Product Features

• Plasma isolated from clinically confirmed MPS III Sanfilippo syndrome donors
• Research Use Only (RUO)
• Rigorous donor screening and sample quality checks
• Standardized collection and processing SOPs
• Suitable for downstream applications such as ELISA, LC-MS/MS glycosaminoglycan analysis and qPCR
• Standard and custom volumes; volumes reported per lot

De-identified Donor Data

• Age, sex, race, medication, diagnosis method, disease severity/stage
• Optional: comorbidities, lab values, and clinical history
• Subtype and genotype reported per lot where captured
• Additional MPS III-specific clinical fields available on request

Applications

• Plasma heparan sulfate and total glycosaminoglycan quantification by mass spectrometry
• Subtype-discriminating non-reducing-end biomarker method development
• Pharmacodynamic endpoint development for enzyme replacement, gene therapy and substrate reduction programmes
• Neurodegeneration and neuroinflammation biomarker discovery in a peripherally accessible matrix
• Natural history biomarker studies across disease stages and subtypes
• Plasma proteomic and metabolomic discovery in lysosomal storage disease
• Newborn screening and diagnostic confirmatory assay development
• Reference and control material sourcing for rare disease diagnostics

Other MPS III Sanfilippo Syndrome Specimen Types

• MPS III Sanfilippo Syndrome Serum
• MPS III Sanfilippo Syndrome PBMC
• MPS III Sanfilippo Syndrome Whole Blood
• Mucopolysaccharidosis Whole Blood
• MPS II Hunter Syndrome Whole Blood

Compliance and Quality Assurance

• IRB-approved protocols
• Informed donor consent
• HIPAA-compliant handling of donor information
• Standardized collection and processing SOPs

Ordering & Customization

Samples are available in both standard and custom volumes to meet your research needs. For pricing, international shipments or country-specific documentation requirements, please contact us at learnmore@sanguinebio.com to ensure compliance with your local regulations. To compare collection formats or check wider availability, visit our human plasma page.